object
viru
infect
underevalu
older
adult
sever
acut
respiratori
infect
sari
aim
evalu
clinic
impact
combin
pointofcar
molecular
viral
test
serum
procalcitonin
pct
level
antibiot
stewardship
emerg
depart
ed
design
prospect
twincent
cohort
studi
conduct
januari
march
set
particip
older
adult
patient
present
ed
sari
receiv
rapid
molecular
test
respiratori
virus
pct
test
measur
evalu
clinic
impact
compar
outcom
sari
patient
experiment
cohort
propens
scoreematch
histor
cohort
primari
outcom
proport
antibiot
discontinu
deescal
ed
secondari
outcom
includ
durat
intraven
antibiot
length
hospit
stay
mortal
result
total
patient
includ
patient
experiment
group
patient
control
group
onefourth
patient
experiment
group
test
posit
viru
compar
control
experiment
group
significantli
higher
proport
antibiot
discontinu
deescal
ed
vs
p
neuraminidas
inhibitor
use
vs
p
shorter
durat
intraven
antibiot
vs
day
p
conclus
implic
combin
rapid
viral
surveil
pct
test
use
strategi
earli
detect
potenti
viral
epidem
antibiot
stewardship
cluster
viral
respiratori
infect
nurs
home
common
patient
transfer
nurs
home
ed
may
benefit
approach
amda
e
societi
postacut
longterm
care
medicin
communityacquir
respiratori
tract
infect
among
common
reason
emerg
depart
ed
visit
caus
viral
bacteri
pathogen
identif
pathogen
caus
symptom
critic
rapid
institut
adequ
antivir
antibiot
therapi
challeng
differenti
viral
bacteri
pathogen
patient
viral
respiratori
infect
usual
underdetect
unnecessari
antibacteri
agent
like
administ
therefor
laboratori
test
provid
accur
time
determin
infecti
agent
associ
viral
respiratori
diseas
import
broad
array
test
avail
detect
viral
respiratori
agent
rapid
antigen
test
avail
influenza
b
respiratori
syncyti
viru
rsv
test
low
sensit
specif
author
declar
conflict
interest
molecular
diagnost
test
use
polymeras
chain
reaction
pcr
method
detect
rna
dna
infecti
agent
show
high
sensit
specif
technic
challeng
time
consum
advent
sensit
pointofcar
poc
molecular
detect
method
made
rapid
diagnosi
respiratori
viru
infect
possibl
filmarray
system
biofir
diagnost
inc
salt
lake
citi
ut
desktop
autom
realtim
pcr
system
integr
sampl
prepar
amplif
detect
analysi
complet
process
deliv
result
hour
respiratori
panel
detect
respiratori
virus
bacteri
target
singl
reaction
initi
studi
demonstr
poc
multiplex
pcr
system
identifi
previous
underevalu
viral
atyp
infect
ed
dyspneic
patient
addit
inform
rapid
respiratori
infect
test
may
also
chang
physician
antibioticprescrib
behavior
enabl
time
appropri
treatment
hospit
length
stay
direct
medic
cost
patient
identifi
respiratori
pathogen
decreas
despit
avail
highli
accur
viral
test
result
discontinu
deescal
antibiot
still
rais
concern
mix
virusbacteria
coinfect
especi
influenza
pneumococcu
common
older
adult
studi
propos
diagnost
approach
combin
multiplex
pcr
respiratori
panel
procalcitonin
pct
test
better
guid
antibiot
treatment
pct
precursor
calcitonin
constitut
secret
c
cell
thyroid
gland
k
cell
lung
healthi
individu
pct
normal
undetect
ngml
stimul
endotoxin
pct
rapidli
produc
parenchym
tissu
throughout
bodi
unlik
creactiv
protein
pct
respond
steril
inflamm
viral
infect
distinct
characterist
make
pct
valuabl
diagnost
marker
multipl
random
control
trial
demonstr
pct
level
mgl
guid
decis
withhold
antibiot
stop
therapi
earli
sinc
approv
filmarray
respiratori
panel
test
studi
evalu
clinic
impact
implement
multiplex
pcr
respiratori
panel
patient
less
sever
acut
reparatori
ill
date
studi
focus
older
adult
sever
acut
respiratori
ill
older
adult
vulner
respiratori
viru
infect
undifferenti
clinic
manifest
bacteri
viral
infect
antibiot
overus
popul
common
studi
aim
assess
impact
implement
diagnost
algorithm
combin
rapid
respiratori
viral
surveil
pct
test
older
patient
present
ed
sever
acut
respiratori
ill
conduct
prospect
cohort
studi
ed
urban
medic
center
clinic
impact
evalu
comparison
experiment
cohort
propens
score
ps
ematch
histor
cohort
conduct
prospect
multicent
observ
studi
sampl
ed
patient
present
acut
sever
respiratori
ill
ed
urban
medic
center
particip
project
annual
ed
censu
around
one
medic
center
studi
period
includ
januari
march
defin
preerespiratori
panel
system
implement
period
januari
decemb
month
posterespiratori
panel
system
implement
period
januari
march
multiplex
pcr
kit
use
rapid
pcr
respiratori
panel
system
calibr
remain
kit
aim
use
among
studi
patient
howev
plan
end
date
studi
could
reach
target
sampl
size
therefor
extens
experiment
group
made
collect
suffici
sampl
trial
approv
institut
review
board
human
research
particip
center
patient
age
year
older
present
ed
acut
sever
respiratori
ill
elig
inclus
defin
case
sever
acut
respiratori
ill
accord
world
health
organ
case
definit
defin
sever
acut
respiratori
ill
adult
physiciandiagnos
lower
respiratori
tract
infect
puls
oxygen
satur
spo
present
less
respiratori
rate
breathsmin
requir
intub
mechan
ventil
basic
demograph
clinic
inform
specimen
collect
day
admiss
episod
lower
respiratori
tract
infect
defin
acut
pulmonari
diseas
without
acut
respiratori
failur
includ
pneumonia
influenzalik
ill
acut
exacerb
chronic
respiratori
ill
includ
exacerb
chronic
obstruct
pulmonari
diseas
asthma
bronchiectasi
exclus
criteria
includ
patient
receiv
palli
care
declin
nasopharyng
swab
particip
provid
written
inform
consent
filmarray
respiratori
panel
biofir
diagnost
inc
detect
virus
rsv
influenza
influenza
b
adenoviru
parainfluenza
viru
rhinovirusenteroviru
human
metapneumoviru
human
coronaviru
atyp
bacteria
bordetella
pertussi
mycoplasma
pneumonia
chlamydia
pneumonia
collect
nasopharyng
swab
use
nylon
flock
swab
immedi
place
univers
transport
media
utm
studi
nurs
collect
sampl
specimen
utm
test
accord
manufactur
instruct
blood
sampl
collect
within
hour
admiss
pct
concentr
measur
use
immunoluminometr
assay
detect
limit
ngml
brahm
pctsensit
kryptor
thermo
fisher
scientif
brahm
gmbh
respiratori
swab
blood
sampl
test
soon
receiv
laboratori
studi
period
studi
nurs
identifi
elig
patient
explain
studi
protocol
treat
physician
patient
elig
patient
receiv
rapid
molecular
test
respiratori
virus
pct
test
result
respiratori
panel
pct
test
commun
treat
physician
directli
studi
nurs
soon
avail
kept
medic
record
studi
nurs
remind
treat
physician
recommend
antibiot
treatment
base
differ
viral
pct
test
result
detect
influenza
initi
isol
neuraminidas
inhibitor
use
detect
viru
elev
serum
pct
level
ngml
may
indic
possibl
superimpos
bacteri
infect
justifi
continu
use
antibacteri
treatment
patient
noneinfluenza
viru
infect
combin
antivir
antibacteri
treatment
patient
influenza
infect
posit
result
respiratori
viru
low
serum
pct
level
stabl
clinic
manifest
may
allow
earli
discontinu
deescal
empir
antibiot
deescal
defin
chang
narrowerspectrum
antibiot
shift
intraven
antibiot
oral
form
neg
respiratori
viru
test
result
low
serum
level
pct
ngml
would
prompt
clinician
consid
noninfecti
caus
respiratori
distress
acut
exacerb
obstruct
airway
diseas
acut
decompens
heart
failur
fluid
overload
inform
regard
laboratori
test
antibiot
antivir
therapi
administr
durat
intraven
antibiot
treatment
length
intens
care
unit
stay
length
hospit
stay
mortal
obtain
electron
health
record
compar
outcom
durat
intraven
antibiot
use
histor
cohort
similar
baselin
characterist
clinic
present
clinic
impact
measur
via
proport
stop
deescal
antibiot
neuraminidas
inhibitor
use
ed
durat
intraven
antibiot
treatment
length
hospit
stay
length
intens
care
unit
stay
mortal
overal
allcaus
mortal
evalu
clinic
impact
combin
respiratori
panel
pct
test
outcom
patient
sever
acut
respiratori
ill
establish
histor
cohort
includ
patient
present
ed
sever
acut
respiratori
ill
januari
decemb
databas
includ
follow
demograph
clinic
present
present
viral
sign
laboratori
data
imag
result
ed
admiss
medic
use
ed
hospit
cours
discharg
statu
use
psmatch
techniqu
select
group
patient
similar
demograph
comorbid
diagnos
vital
sign
laboratori
result
experiment
cohort
receiv
respiratori
panel
pct
test
increas
statist
power
analysi
perform
match
final
cohort
includ
older
adult
sever
acut
respiratori
ill
patient
receiv
respiratori
panel
pct
test
psmatch
control
patient
composit
cohort
use
assess
clinic
impact
rapid
respiratori
viral
surveil
pct
test
baselin
characterist
summar
use
appropri
descript
statist
categor
variabl
present
frequenc
percentag
compar
use
chisquar
test
continu
variabl
present
median
interquartil
rang
compar
nonparametr
mannwhitney
u
test
number
differ
respiratori
viral
isol
mean
serum
level
pct
differ
viral
infect
shown
bar
graph
select
control
patient
built
ps
match
ps
defin
condit
probabl
test
respiratori
panel
pct
deriv
logist
regress
model
includ
follow
potenti
predictor
demograph
comorbid
present
vital
sign
laboratori
result
admiss
diagnos
verifi
balanc
baselin
covari
ps
match
made
standard
differ
plot
ensur
minimum
differ
baselin
covari
group
patient
supplementari
figur
psmatch
cohort
compar
outcom
current
cohort
psmatch
histor
cohort
use
logist
regress
model
adjust
residu
differ
baselin
covari
statist
analys
perform
sa
sa
inc
cari
nc
p
valu
deem
signific
total
patient
enrol
studi
exclud
miss
data
loss
followup
final
older
adult
patient
sever
acut
respiratori
ill
includ
studi
analysi
patient
test
posit
respiratori
viru
patient
sick
hospit
demograph
present
vital
sign
laboratori
test
result
underli
comorbid
experiment
control
cohort
shown
tabl
experiment
cohort
mean
age
year
male
diabet
cancer
chronic
pulmonari
diseas
lead
comorbid
pneumonia
chronic
obstruct
pulmonari
diseas
acut
exacerb
acut
respiratori
failur
preval
diagnos
control
cohort
compar
distribut
aforement
characterist
except
includ
fewer
patient
dementia
chronic
liver
diseas
experiment
group
patient
test
posit
respiratori
viru
includ
influenza
b
viru
rsv
human
rhinovirusenteroviru
coronaviru
parainfluenza
viru
type
human
metapneumoviru
control
group
patient
diagnos
influenza
significantli
lower
experiment
group
p
tabl
patient
test
posit
viru
pct
level
lower
ngml
coronaviru
influenza
human
rhinovirusenteroviru
infect
higher
serum
level
pct
figur
compar
control
group
patient
experiment
group
antibiot
deescal
vs
p
receiv
neuraminidas
inhibitor
ed
vs
p
shorter
durat
intraven
antibiot
use
although
patient
experiment
group
trend
antibiot
discontinu
small
number
patient
prevent
meaning
comparison
neither
inhospit
mortal
significantli
differ
group
account
residu
covari
differ
ps
match
perform
logist
linear
regress
adjust
age
temperatur
chronic
liver
diseas
dementia
result
reveal
rapid
pcr
respiratori
panel
pct
test
associ
increas
odd
discontinu
deescal
antibiot
odd
ratio
confid
interv
ci
increas
odd
neuraminidas
inhibitor
prescript
ci
shorter
durat
intraven
antibiot
ci
differ
length
hospit
stay
mortal
tabl
prospect
cohort
studi
report
clinic
impact
rapid
molecular
diagnosi
respiratori
pathogen
conjunct
pct
test
older
adult
patient
present
ed
sever
acut
respiratori
ill
result
show
older
adult
sever
acut
respiratori
ill
patient
respiratori
viru
infect
influenza
rsv
human
rhinovirusenteroviru
lead
pathogen
demonstr
new
diagnost
approach
associ
increas
discontinu
deescal
antibiot
reduc
length
intraven
antibiot
treatment
improv
influenza
detect
antivir
use
find
consist
previou
studi
brendish
et
al
show
patient
receiv
respiratori
panel
test
like
undergo
singl
dose
brief
cours
antibiot
treatment
respiratori
panel
test
also
associ
reduc
length
stay
improv
influenza
detect
antivir
use
howev
find
routin
use
respiratori
panel
test
could
reduc
proport
patient
treat
antibiot
ascrib
initi
antibiot
result
pct
mani
patient
prepost
studi
show
use
respiratori
panel
decreas
time
diagnosi
respiratori
virus
hospit
admiss
rate
length
stay
number
chest
radiograph
durat
antimicrobi
use
gelfer
et
al
combin
respiratori
panel
pct
test
found
signific
differ
overal
antibiot
exposur
experiment
standardofcar
group
nevertheless
found
significantli
fewer
patient
discharg
antibiot
shorter
durat
therapi
subgroup
patient
posit
viral
neg
pct
test
result
stress
import
proactiv
commun
antibiot
stewardship
team
physician
result
show
propos
diagnost
approach
could
reduc
intraven
antibiot
treatment
durat
day
without
compromis
patient
outcom
histor
advis
complet
cours
intraven
antibiot
treatment
despit
resolut
clinic
symptom
howev
littl
evid
support
practic
overus
antibiot
associ
increas
risk
clostridioid
difficil
infect
prolong
cours
intraven
antibiot
may
increas
risk
advers
drug
event
organ
dysfunct
mortal
noteworthi
identif
respiratori
viru
alon
may
suffici
reduc
antibiot
use
concern
regard
mix
virusbacteria
coinfect
especi
influenza
pneumococcu
infect
low
serum
level
pct
may
help
allevi
concern
mix
infect
addit
commun
result
treat
physician
import
although
formal
antibiot
stewardship
team
studi
nurs
commun
result
treat
physician
promot
antibiot
stewardship
anoth
find
underdiagnosi
influenza
older
adult
patient
older
adult
patient
less
like
undergo
providerord
influenza
test
usual
lack
typic
present
influenzalik
ill
may
present
respiratori
distress
confus
recent
studi
show
diagnosi
influenza
base
clinic
ground
alon
associ
suboptim
sensit
specif
effect
estim
dichotom
outcom
calcul
logist
regress
wherea
continu
outcom
calcul
use
quantil
regress
model
adjust
covari
balanc
ps
match
includ
age
temperatur
chronic
liver
diseas
dementia
chronic
obstruct
pulmonari
diseas
acut
exacerb
propos
algorithm
respiratori
viru
infect
diagnosi
antibiot
stewardship
may
also
implic
nurs
home
nh
resid
acut
respiratori
viru
infect
outbreak
common
problem
nh
recent
systemat
review
report
annual
incid
influenza
rsv
infect
longterm
care
facil
influenza
rsv
human
metapneumoviru
third
common
caus
pathogen
nh
respiratori
infect
outbreak
nh
often
onsit
equip
evalu
suspect
infect
therefor
lower
threshold
antibiot
prescript
common
estim
approxim
twothird
nh
resid
receiv
antibiot
year
treatment
inappropri
nh
becom
reservoir
resist
bacteria
within
commun
although
present
protocol
implement
nh
use
among
sever
nh
patient
transfer
ed
less
sever
outbreak
nasopharyng
sampl
nh
resid
collect
sent
contract
laboratori
respiratori
panel
test
earli
detect
acut
respiratori
infect
enabl
earli
isol
infect
patient
earli
antivir
drug
administr
prevent
contain
respiratori
viru
infect
outbreak
cost
import
consider
largescal
clinic
implement
rapid
multiplex
pcr
test
previou
analys
show
rapid
multiplex
pcr
test
costeffect
test
strategi
detect
influenza
children
costeffect
respiratori
panel
test
highli
influenc
preval
influenza
proport
patient
treat
antivir
signific
improv
influenza
diagnosi
antivir
treatment
studi
suggest
combin
respiratori
panel
pct
test
may
costeffect
studi
set
specul
howev
requir
futur
valid
result
interpret
light
sever
limit
first
pct
test
use
comparison
cohort
determin
impact
viral
panel
pct
test
separ
second
studi
nurs
enrol
patient
work
hour
weekday
select
spectrum
bia
less
like
find
signific
differ
outcom
patient
present
ed
differ
time
shift
third
postdischarg
followup
data
histor
comparison
cohort
retriev
therefor
could
compar
durat
oral
antibiot
cohort
reduct
intraven
antibiot
durat
alon
import
shown
strong
risk
factor
develop
resist
bacteria
strain
fourth
gener
result
set
taken
consider
long
hospit
durat
studi
due
old
age
sever
ill
low
hospit
cost
lastli
incid
variou
respiratori
virus
may
vari
across
season
studi
period
strength
studi
includ
older
adult
popul
twincent
prospect
cohort
design
simpl
antibiot
stewardship
algorithm
comparison
psmatch
cohort
find
studi
support
use
rapid
multiplex
pcr
respiratori
panel
conjunct
pct
test
earli
diagnosi
respiratori
viral
infect
inform
optim
antibiot
use
older
adult
patient
present
ed
sever
acut
respiratori
ill
respiratori
viral
infect
outbreak
common
nurs
home
perform
propos
diagnost
approach
patient
transfer
nh
may
enabl
earli
detect
caus
pathogen
earli
isol
infect
patient
cost
per
test
still
high
institut
develop
protocol
prevent
indiscrimin
test
multiplex
pcr
provid
proactiv
realtim
feedback
treat
physician
antimicrobi
stewardship
studi
need
assess
increment
valu
multiplex
pcr
viral
test
compar
pct
test
alon
manag
patient
sever
acut
respiratori
infect
ed
